Chardan Capital Initiates Coverage on ProQR Therapeutics NV(NASDAQ:PRQR). The shares have been rated Neutral. The rating by Chardan Capital was issued on Jun 20, 2016.
ProQR Therapeutics NV (PRQR) shares turned negative on Fridays trading session with the shares closing down -0.46 points or -9.09% at a volume of 28,438. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $5.17. The peak price level was also seen at $5.17 while the days lowest was $4.58. Finally the shares closed at $4.6. The 52-week high of the shares is $20.05 while the 52-week low is $3.48. According to the latest information available, the market cap of the company is $107 M.
ProQR Therapeutics N.V. (ProQR) formerly ProQR Therapeutics B.V. is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of Ribo Nucleic Acid-based therapeutics for the treatment of severe genetic disorders. Utilizing its Ribo Nucleic Acid (RNA) repair technologies the Company is developing a pipeline in severe genetic disorders such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). The Company designs its therapeutic candidates to specifically target and repair the defective messenger RNA or Messenger Ribonucleic Acid (mRNA) that is transcribed from a mutated gene in order to restore the expression and function of normal or wild-type protein. The Company’s product candidates include QR-010 and QR-110.